MEDICINE, vol.98, no.33, 2019 (Journal Indexed in SCI)
Article / Article
Title of Journal :
breast, cancer, checkpoint blockade, immunotherapy, PD-L1, PD-L1 EXPRESSION, CLINICAL-SIGNIFICANCE, SURGICAL RESECTION, POOR-PROGNOSIS, CELLS, HETEROGENEITY, PREDICTS, THERAPY, PDL1
Conventional therapy modalities for advanced breast cancer are problematic, whereas checkpoint blockade immunotherapy has been considered as a promising approach. This study aims to determine programmed death-ligand 1 (PD-L1) expression and methylation status of PD-L1 promoter in primary tumor tissue and metastatic foci of patients with stage IV breast cancer.